Garmultin-A Incites Apoptosis in CB3 Cells Through miR-17-5p by Attenuating Poly (ADP-Ribose) Polymerase-1. Issue 4 (11th October 2022)
- Record Type:
- Journal Article
- Title:
- Garmultin-A Incites Apoptosis in CB3 Cells Through miR-17-5p by Attenuating Poly (ADP-Ribose) Polymerase-1. Issue 4 (11th October 2022)
- Main Title:
- Garmultin-A Incites Apoptosis in CB3 Cells Through miR-17-5p by Attenuating Poly (ADP-Ribose) Polymerase-1
- Authors:
- Qiu, Jianfei
Chen, Li
Yang, Jue
Varier, Krishnapriya M.
Gajendran, Babu
Yao, Yao
Liu, Wuling
Song, Jingrui
Rao, Qing
Long, Qun
Yuan, Chunmao
Hao, Xiaojiang
Li, Yanmei - Abstract:
- Background: Leukemia accounts for a large number of deaths, worldwide, every year. Treating this ailment is always a challenging job. Recently, oncogenic miRNA leading to apoptosis are highly promising targets of many natural products. In this study, Garmultin-A (GA), isolated from the bark of Garcinia multiflora, was elucidated for its anti-leukemic effect in CB3 cells. Methods: The effect of the compound on CB3 cell viability was detected by MTT assay and apoptosis by FITC Annexin V/PI and Hochest 33258 staining. The western blot analysis assessed the BAX, BCL2, cMYC, pERK, and PARP-1 protein levels. Autodock analysis predicted the ligand–protein interactions. q-RT-PCR quantified the miR-17-5p expression. Luciferase assay confirmed the interaction between PARP-1 and miR-17-5p. Results: We uncover that GA leads to apoptosis by inducing overexpression of miR-17-5p and significantly downregulate PARP-1 protein levels in CB3 cells. The overexpression of miR-17-5p promotes apoptosis, and the miR-17-5p antagomirs restore GA-triggered apoptosis. Notably, we disclose that PARP-1 is a direct target of miR-17-5p. Increased pro-apoptotic and reduced anti-apoptosis protein levels were also observed in GA-treated CB3 cells. Conclusion: These results provide critical insights that GA could induce apoptosis in CB3 cells through targeting miR-17-5p by attenuating PARP-1. Thus, GA could act as a novel therapeutic agent for erythroleukemia.
- Is Part Of:
- Dose-response. Volume 20:Issue 4(2022)
- Journal:
- Dose-response
- Issue:
- Volume 20:Issue 4(2022)
- Issue Display:
- Volume 20, Issue 4 (2022)
- Year:
- 2022
- Volume:
- 20
- Issue:
- 4
- Issue Sort Value:
- 2022-0020-0004-0000
- Page Start:
- Page End:
- Publication Date:
- 2022-10-11
- Subjects:
- Garmultin-A -- leukemia -- apoptosis -- miR-17-5p -- PARP-1
Dose-response relationship (Biochemistry) -- Periodicals
Drugs -- Dose-response relationship -- Periodicals
Drugs -- Physiological effect -- Periodicals
Hormesis -- Periodicals
Dose-Response Relationship, Drug -- Periodicals
Dose-response relationship (Biochemistry)
Drugs -- Dose-response relationship
Drugs -- Physiological effect
Periodicals
571.634 - Journal URLs:
- http://journals.sagepub.com/home/dos ↗
http://dos.sagepub.com/ ↗
http://dose-response.metapress.com ↗
http://www.dose-response.com/ ↗
http://www.ncbi.nlm.nih.gov/pmc/journals/614/ ↗
http://www.sagepublications.com/ ↗ - DOI:
- 10.1177/15593258221130681 ↗
- Languages:
- English
- ISSNs:
- 1559-3258
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 24221.xml